Evidence map›Paper›PMID 31388932›Full record

Trial reportInternational journal of hematology2019

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Meletios A Dimopoulos, Philippe Moreau, Shinsuke Iida, Shang-Yi Huang, Naoki Takezako, Wee Joo Chng, Anita Zahlten-Kumeli, Martina A Sersch, Julia Li, Mei Huang and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01568866 (A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01568866 phase3completednot on this map

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

TypeinterventionalSponsorAmgenRan2012 to 2018Enrolled929ConditionsMultiple MyelomaArmsCarfilzomib, Bortezomib, Dexamethasone
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Observational
  4. Observational
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meletios A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, 80 Vas Sofias Avenue, 11528, Athens, Greece. mdimop@med.uoa.gr.
Philippe MoreauUniversity of Nantes, Nantes, France.
Shinsuke IidaNagoya City University Hospital, Nagoya, Japan.
Shang-Yi HuangNational Taiwan University Hospital, Taipei City, Taiwan.
Naoki TakezakoNational Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan.
Wee Joo ChngNational University Cancer Institute, National University Health System, Singapore, Singapore.
Anita Zahlten-KumeliAmgen Inc., Thousand Oaks, CA, USA.
Martina A SerschAmgen Inc., Thousand Oaks, CA, USA.
Julia LiAmgen Inc., Thousand Oaks, CA, USA.
Mei HuangAmgen Inc., Thousand Oaks, CA, USA.
Jae Hoon LeeGil Medical Center, Gachon University College of Medicine, Incheon, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carfilzomib is an irreversible proteasome inhibitor used for the treatment of relapsed and/or refractory multiple myeloma (RRMM). We evaluated the efficacy and safety of carfilzomib in subgroups of Asian patients in the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. In ENDEAVOR, patients received carfilzomib twice-weekly (56 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAsian PeopleBortezomibDexamethasoneDrug Administration ScheduleHumansMultiple MyelomaOligopeptidesProteasome InhibitorsRisk AssessmentSurvival RateTreatment OutcomeBortezomibcarfilzomibDexamethasoneOligopeptidesProteasome InhibitorsAsian populationCarfilzomibClinical trialsRelapsed and/or refractory multiple myeloma

Identifiers

PMID31388932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.